These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 15851215)

  • 21. An orwellian discourse on the meaning and measurement of noninferiority.
    Diamond GA; Kaul S
    Am J Cardiol; 2007 Jan; 99(2):284-7. PubMed ID: 17223435
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mortality as an endpoint in atrial fibrillation.
    Beyerbach DM; Zipes DP
    Heart Rhythm; 2004 Jul; 1(2 Suppl):B8-18, discussion B18-9. PubMed ID: 15851134
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Newer phase II trial designs gaining ground.
    Benowitz S
    J Natl Cancer Inst; 2007 Oct; 99(19):1428-9. PubMed ID: 17895467
    [No Abstract]   [Full Text] [Related]  

  • 24. Rationale and design of ACTIVE: the atrial fibrillation clopidogrel trial with irbesartan for prevention of vascular events.
    ; ; Connolly S; Yusuf S; Budaj A; Camm J; Chrolavicius S; Commerford PJ; Flather M; Fox KA; Hart R; Hohnloser S; Joyner C; Pfeffer M; Anand I; Arthur H; Avezum A; Bethala-Sithya M; Blumenthal M; Ceremuzynski L; De Caterina R; Diaz R; Flaker G; Frangin G; Franzosi MG; Gaudin C; Golitsyn S; Goldhaber S; Granger C; Halon D; Hermosillo A; Hunt D; Jansky P; Karatzas N; Keltai M; Lanas F; Lau CP; Le Heuzey JY; Lewis BS; Morais J; Morillo C; Oto A; Paolasso E; Peters RJ; Pfisterer M; Piegas L; Pipillis T; Proste C; Sitkei E; Swedberg K; Synhorst D; Talajic M; Trégou V; Valentin V; van Mieghem W; Weintraub W; Varigos J
    Am Heart J; 2006 Jun; 151(6):1187-93. PubMed ID: 16781218
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nonconventional clinical trial designs: approaches to provide more precise estimates of treatment effects with a smaller sample size, but at a cost.
    Howard G
    Stroke; 2007 Feb; 38(2 Suppl):804-8. PubMed ID: 17261743
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Patient preferences and clinical trial design and interpretation: appreciation and critique of a paper by Feine, Awad & Lund.
    Bradley C
    Community Dent Oral Epidemiol; 1999 Apr; 27(2):85-8. PubMed ID: 10226717
    [No Abstract]   [Full Text] [Related]  

  • 27. The value of cardiovascular hospitalization as an endpoint for clinical atrial fibrillation research.
    Nieuwlaat R
    Europace; 2011 May; 13(5):601-2. PubMed ID: 21515593
    [No Abstract]   [Full Text] [Related]  

  • 28. Science, language, intuition, and the many meanings of quality of life.
    Browman GP
    J Clin Oncol; 1999 Jun; 17(6):1651-3. PubMed ID: 10561200
    [No Abstract]   [Full Text] [Related]  

  • 29. Randomized clinical trials in surgery: why do we need them?
    Balch CM
    J Thorac Cardiovasc Surg; 2006 Aug; 132(2):241-2. PubMed ID: 16872941
    [No Abstract]   [Full Text] [Related]  

  • 30. The Primary Outcome Is Positive - Is That Good Enough?
    Pocock SJ; Stone GW
    N Engl J Med; 2016 Sep; 375(10):971-9. PubMed ID: 27602669
    [No Abstract]   [Full Text] [Related]  

  • 31. Atrial fibrillation and the risk of death in patients with heart failure: a literature-based meta-analysis.
    Wasywich CA; Pope AJ; Somaratne J; Poppe KK; Whalley GA; Doughty RN
    Intern Med J; 2010 May; 40(5):347-56. PubMed ID: 19460059
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Randomized two-stage Phase II clinical trial designs based on Barnard's exact test.
    Shan G; Ma C; Hutson AD; Wilding GE
    J Biopharm Stat; 2013; 23(5):1081-90. PubMed ID: 23957517
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Rationale and design of ATHENA: A placebo-controlled, double-blind, parallel arm Trial to assess the efficacy of dronedarone 400 mg bid for the prevention of cardiovascular Hospitalization or death from any cause in patiENts with Atrial fibrillation/atrial flutter.
    Hohnloser SH; Connolly SJ; Crijns HJ; Page RL; Seiz W; Torp-Petersen C
    J Cardiovasc Electrophysiol; 2008 Jan; 19(1):69-73. PubMed ID: 18031520
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Health-related quality-of-life as co-primary endpoint in randomized clinical trials in oncology.
    Fiteni F; Pam A; Anota A; Vernerey D; Paget-Bailly S; Westeel V; Bonnetain F
    Expert Rev Anticancer Ther; 2015; 15(8):885-91. PubMed ID: 26027598
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Alternative endpoints for mortality in studies of patients with atrial fibrillation: the AFFIRM study experience.
    Wyse DG; Slee A; Epstein AE; Gersh BJ; Rocco T; Vidaillet H; Volgman A; Weiss R; Shemanski L; Greene HL;
    Heart Rhythm; 2004 Nov; 1(5):531-7. PubMed ID: 15851214
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pragmatic trials: is this a useful method in nursing research?
    King KM; Thompson DR
    J Clin Nurs; 2008 Jun; 17(11):1401-2. PubMed ID: 18482137
    [No Abstract]   [Full Text] [Related]  

  • 37. Testing homogeneity of two zero-inflated Poisson populations.
    Tse SK; Chow SC; Lu Q; Cosmatos D
    Biom J; 2009 Feb; 51(1):159-70. PubMed ID: 19219907
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Design and endpoints of clinical trials in hepatocellular carcinoma.
    Llovet JM; Di Bisceglie AM; Bruix J; Kramer BS; Lencioni R; Zhu AX; Sherman M; Schwartz M; Lotze M; Talwalkar J; Gores GJ;
    J Natl Cancer Inst; 2008 May; 100(10):698-711. PubMed ID: 18477802
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Overview of endpoints in atrial fibrillation studies.
    Wyse DG
    Heart Rhythm; 2004 Jul; 1(2 Suppl):B3-7, discussion B7. PubMed ID: 15851133
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Development of methodology for conducting clinical trials in frontotemporal lobar degeneration.
    Knopman DS; Kramer JH; Boeve BF; Caselli RJ; Graff-Radford NR; Mendez MF; Miller BL; Mercaldo N
    Brain; 2008 Nov; 131(Pt 11):2957-68. PubMed ID: 18829698
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.